Isotretinoin can cause severe, life-threatening birth defects. Preventing pregnancy exposure is therefore part of prescribing the medicine, not an optional addition for patients who take a high dose. In the United States, iPLEDGE coordinates requirements for patients, prescribers and dispensing pharmacies across isotretinoin products. 1, 2
The requirements differ by whether a patient can become pregnant. The clinic must establish the appropriate category and explain the current steps. Do not infer your category from a website example or assume that infertility, irregular periods or a particular contraceptive method automatically removes every requirement.
Why the precautions begin before treatment
Pregnancy can occur before someone recognizes it, and even a brief period of isotretinoin exposure can harm a developing fetus. The prevention plan therefore starts before the first capsule. A negative test describes a point in time; it does not protect against a pregnancy that begins afterward. 3, 4
Patients who can become pregnant need pretreatment testing and a prevention plan that meets the applicable program requirements. The prescriber should discuss acceptable contraceptive methods or the program's abstinence requirements, including what to do if the plan changes.
Do not begin using someone else's capsules while waiting for your own appointment or authorization. The fact that you intend to complete the process later does not make the first doses safe.
What all US patients need
iPLEDGE applies to patients who cannot become pregnant as well as those who can. Prescribers and pharmacies must also participate. Enrollment, counseling, authorization and dispensing requirements work together; a prescription alone does not bypass them. 1, 2
- Complete the enrollment and consent process the clinic provides.
- Understand the relevant risks before the first dose.
- Use the pharmacy and authorization process required for treatment.
- Attend the follow-up appointments and tests your clinician schedules.
- Never share capsules, including with another enrolled patient.
- Do not donate blood during treatment or for one month afterward.
Your clinic should explain what happens if a pharmacy lacks stock, an appointment moves or a test result arrives late. Solving those issues before a dispensing deadline is usually easier than trying to restart the process after it passes.
Testing and contraception for patients who can become pregnant
US labeling describes pregnancy tests before treatment, during the course, at completion and one month after stopping. It also sets out contraception requirements for one month before treatment, throughout treatment and for one month afterward. The clinic must explain the details that apply to you. 3, 4
Two acceptable methods of contraception generally form part of the US program unless the patient meets its abstinence requirements. Not every method qualifies in the same way. Do not assume that a particular pill, fertility tracking or occasional condom use meets the program's rules.
Tell the prescriber if you stop contraception, have unprotected sex, miss a period or suspect pregnancy. The response may require stopping isotretinoin and urgent clinical advice. Waiting for the next scheduled appointment can delay a time-sensitive assessment.
Prescription windows and missed steps
For patients who can become pregnant, the dispensing process includes a short prescription window linked to the pregnancy test. The clinic and pharmacy should confirm the exact timing and whether all required steps have cleared before you travel to collect the medicine.
A missed window does not authorize using leftover capsules, buying another supply elsewhere or repeating a test without checking the process. Contact the clinic for the correct next step. Instructions about repeat testing and waiting periods have changed over time, which makes old patient posts an unreliable guide.
| Situation | Who can resolve it | What to have ready |
|---|---|---|
| Enrollment or category uncertainty | Prescribing clinic | Your program details and the question you need clarified |
| Test timing or an unreadable result | Prescriber and testing service | Test date, method and the clinic's instructions |
| Pharmacy stock or authorization problem | Pharmacy and prescriber | Exact product, prescription date and authorization status |
| Missed dispensing window | Prescribing clinic | Dates of the test, prescription and attempted collection |
| Possible pregnancy | Prescriber urgently, with appropriate pregnancy care | Last dose, pregnancy test information and relevant dates |
FDA's announced 2026 changes
FDA approved modifications intended to reduce administrative burdens while maintaining pregnancy precautions. Its June 2026 update moved the planned implementation date to November 15, 2026. As of this page's November 9, 2026 review date, that announced date is still ahead. Do not assume that every future workflow change already operates in your account. 1
The announced changes include prescriber discretion over some pregnancy testing outside a medical setting during and after treatment, revisions to the response after a missed first prescription window, and changes affecting documentation or dispensing for patients who cannot become pregnant. Pretreatment pregnancy tests still require a medical setting under FDA's stated approach.
FDA has also described enforcement discretion before full implementation. That makes the prescriber's current process and the official program instructions more useful than a rigid rule copied from an older article. Confirm what applies at the time of your prescription.
If pregnancy might have occurred
Stop isotretinoin immediately and contact the prescriber urgently if you become pregnant or think you may be pregnant. Obtain medical advice after unprotected sex or a failure of the agreed prevention method rather than waiting for a positive test. The clinician can arrange the appropriate pregnancy assessment and counseling. 3, 4
Do not calculate a safe exposure period from the number of capsules you took. Neither a small dose nor a short course removes the risk. The clinical team needs accurate dates and the product used, without assumptions about what an early scan or lack of symptoms can establish.
The same need for advice applies if pregnancy becomes possible within the post-treatment prevention period. Keep the final follow-up and testing instructions even when the acne has cleared.
Breastfeeding and other countries
The cited US labels do not recommend breastfeeding during treatment. Discuss feeding plans before starting or restarting isotretinoin, since the absence of pregnancy does not settle the separate question of exposure through breast milk. 3, 4
Outside the United States, pregnancy prevention programs and prescribing systems differ. The drug's fetal risk does not change at a border, but iPLEDGE is a US program. A patient in the UK or another country should follow the local specialist's prevention requirements rather than attempt to use a US dispensing timetable.
Does taking isotretinoin as a man create no responsibilities?
Patients who cannot become pregnant still need appropriate counseling, follow-up and the required US enrollment process. They must not share capsules or donate blood during the restricted period. The absence of pregnancy potential does not remove other adverse-effect risks.
Can I use the same contraceptive plan for a second course?
The prescriber needs to review it again. Your health, pregnancy potential, medicines or chosen methods may have changed, and a new course requires the applicable preparation and authorization steps.
What if I cannot meet a program requirement?
Tell the clinic before starting. It can clarify the rule, address a practical barrier or discuss another acne treatment. Concealing a difficulty does not remove it and can expose you to a preventable risk.
Sources
- FDA. iPLEDGE Risk Evaluation and Mitigation Strategy: requirements and 2026 implementation updates. View source
- FDA. Questions and answers on the iPLEDGE REMS. View source
- DailyMed. Isotretinoin capsules prescribing information, revised August 2026. View source
- FDA. Absorica and Absorica LD prescribing information, revised June 2026. View source
- NHS. Isotretinoin: uses, precautions, interactions and side effects. View source